Alendronate for the Prevention of Bone Mineral Loss During Gonadotropin-Releasing Hormone Agonist Therapy

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 48, Issue 10, 2003, Pages 761-766

  Ripps, Barry A ^a   VanGilder, Kelly ^b   Minhas, Brijinder ^b   Welford, Mayla ^b   Mamish, Ziad ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Alendronate; Bone mineral density; Gonadotropin releasing hormone; Gonadotropin releasing hormone agonist

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; GONADORELIN AGONIST; LEUPRORELIN; LIPID; PEPTIDE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIOSIS; ESTROGEN BLOOD LEVEL; FEMALE; FEMUR; HORMONAL THERAPY; HUMAN; LUMBAR SPINE; OSTEOLYSIS; OSTEOPOROSIS; PILOT STUDY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERUS MYOMA;

ADMINISTRATION, ORAL; ADULT; ALENDRONATE; BONE DENSITY; DENSITOMETRY, X-RAY; DOUBLE-BLIND METHOD; ENDOMETRIOSIS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; OSTEOPOROSIS; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0142182625     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Johansen JS, Riis BJ, Hassager C, et al: The effect of gonadotropin-releasing hormone agonist analog on bone metabolism. J Clin Endocrinol Metab 1988;67:701-706
2. Paoletti AM, Serra GG, Cagnacci A, et al: Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril 1996;65:707-710
3. Taga M, Minagauchi H: Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration. Acta Obstet Gynecol Scand 1996;75:162-165
4. Agarwal SJ: Impact of six months of GnRH agonist theapy for endometriosis. J Reprod Med 2002;47:530-534
5. Recker RR, Davies KM, Hinders SM, et al: Bone gain in young adult women. JAMA 1992;268:2403-2408
6. Barbieri R: Hormonal treatment of endometriosis: The estrogen threshold hypothesis. Am J Obstet Gynecol 1992;166:740-745
7. Surrey ES, Gambone JC, Lu JKH, et al: The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis. Fertil Steril 1990;53:620-626
8. Howell R, Edmonds DK, Dowsett M, et al: Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: A randomized controlled trial. Fertil Steril 1995;64:474-481
9. Finkelstein JS, Klibanski A, Arnold AL, et al: Prevention of estrogen deficiency-related bone loss with human parathyroid hormone. JAMA 1998;280:1067-1073
10. Palomba S, Affinito P, Tommselli GA, et al: A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 1998;70:111-118
11. Roux C, Pelissier CX, Listrat V, et al: Bone loss during gonadotropin-releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis Int 1995;5:185-190
12. Surrey ES, Voigt B, Fournet N, et al: Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: The role of cyclic sodium etidronate and low dose norethindrone "add-back" therapy. Fertil Steril 1995;63:747-755
13. Surrey ES: Steroidal and non-steroidal "add-back" therapy: Extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynecologic patient. Fertil Steril 1995;65:673-685
14. Hornstein MD, Surrey ES, Weisberg GW, et al: Lupron Add-Back Study Group: Leuprolide acetate depot and hormonal add-back in endometriosis: A 12 month study. Obstet Gynecol 1998;91:16-24
15. Edmonds D, Howell R: Can hormone replacement therapy be used during medical therapy of endometriosis? Br J Obstet Gynaecol 1994;101:24-26
16. Moghissi KS, Schlaff WD, Olive DL, et al: Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril 1998;69:1056-1062
17. Saag KG, Emkey R, Schnitzer TJ, et al: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-299
18. Surrey ES, Hornstein MD: Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: Long-term follow-up. Obstet Gynecol 2002;99:709-719
19. Ebeling PN, Atley LM, Guthrie JR, et al: Bone turnover markers and bone density across the menopausal transition. JCEM 1996;81:3366-3371
20. Gertz BJ, Shao P, Hanson DA, et al: Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Min Res 1994;9:135-141
21. Garnero P, Weichung JS, Gineyls E, et al: Comparison of new biochemical markers of bone turnover in late menopausal osteoporotic females in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-1700
22. Gertz BJ, Kline WF, Matuszewski BK: Oral bioavailability and dose proportionality of alendronate in postmenopausal women. J Bone Miner Res (suppl) 1991;6:S279